Skip to Main Content

Katherine Seley-Radtke

Contact Information
Office: CHEM 405C
Phone: 410-455-8684


Post-Doctoral Auburn University 1996; Ph.D. Auburn University 1996; B.A. University of South Florida 1992

Professional Interests

Current Fields of Interest:

Medicinal/Synthetic Bioorganic/Organic Chemistry and Drug Design: The Seley-Radtke research group is focused on the discovery, design and synthesis of nucleoside/nucleotide and heterocyclic enzyme inhibitors with chemotherapeutic emphasis in the areas of anticancer, antiviral, antibiotic, and antiparasitic targets. Primary goals include development of potent inhibitors to shut down disease replication pathways through a combination of cross-disciplinary synthetic, biological screening, mechanistic, and structure-based drug design techniques.

One of the primary projects under investigation involves the design and synthesis of flexible nucleoside (“fleximers”) and nucleobases (“flex-bases) inhibitors as a powerful technique to overcome the development of resistance to currently used therapeutics. This approach represents somewhat of a paradigm shift due to the ability of the fleximers and flex-bases to retain full potency when faced with “escape mutations” in biologically critical enzymatic systems. The inherent flexibility of the inhibitors allows them to conformationally adjust to steric and electronic clashes encountered in the binding site, and to engage secondary amino acids not previously involved in the enzyme’s mechanism of action. Potent activity has been uncovered in various viruses including corona viruses such as SARS and MERS-CoV, as well as HIV, HCV and others. In that regard, use of the flex-bases to inhibit the HIV nucleocapsid protein NCp7 is also being pursued. NCp7 is of high interest due to its multifunctional role in HIV replication.

A second project focuses on the use of nucleosides and nucleobases as anticancer agents. For example, the potent activity exhibited by gemcitabine, Ara-C and other related FDA-approved anticancer analogues, has led to numerous structural modifications designed to increase target specificity and potency. Following upon the recent observation that several nucleobase analogues including thiophene-expanded purines, as well as pyrrolo – and thienopyrimidines designed in our laboratories have exhibited selective and highly potent levels of activity against several key cancers including lung, colon, leukemia, renal, and breast cancers (among others), we have initiated a program to elucidate their mechanism of action, as well as to further study their highly promising activity in vitro and in vivo. Most recently, these compounds caused a 50% decrease in tumor growth in preliminary mouse models for melanoma. Additional mechanistic and animal studies are currently underway.

Other projects include synthesis of carbocyclic fleximers as potential Ebola and Marburg drugs by inhibiting methylation of the viral mRNA necessary for proper transcription, as well as to inhibit RNA polymerase, while another employs a strategic use of prodrugs to increase oral bioavailability for a series of tricyclic nucleosides shown to be active against hepatitis C virus (HCV). This latter approach also allows the nucleosides to bypass the first rate-limiting kinase-mediated phosphorylation in the requisite intercellular conversion to their biologically active triphosphate form. Current efforts include applying this approach to other viruses and cancers.

All of the projects being pursued in the Seley-Radtke laboratories employ structure activity relationship (SAR) algorithms for the biological enhancement of lead compounds. Intimately related to the goals of the drug design projects, synthetic organic research focus includes the discovery of unique strategies to solve design challenges using state of the art techniques, including protection/deprotection motifs, enzymatic resolution of enantiomeric mixtures, functional group manipulation, and template directed organometallics for the construction of modified heterocycles, carbohydrates and carbocyclic moieties. In addition, a cross-disciplinary chemical biology approach employs enzymatic assays to survey the effectiveness of the potential drug candidates, as well as to investigate polymerase fidelity with modified nucleotide analogues that possess unique structural advantages for enhanced molecular recognition.

Selected Publications

  1. Alzahrani, K. J.; Khandazhinskaya, A. L.; Matyugina, E. S.; Kochetkov, S. N.; *Seley-Radtke, K. L.; *de Koning, H. P; “Evaluation of the antiprotozoan properties of 5’-norcarbocyclic pyrimidine nucleosides” Bioorganic Med Chem Lett 2017, 27, 3081-3086.
  2. Yates, M.; Raje, M.; Chatterjee, Soloveva, V.; Bavari, S.; Seley-Radtke, K. L. “Antiviral Activity for a series of Flex-nucleoside prodrugs against the filoviruses” Bioorg Med Chem Lett 2017, 27, 2800-2802.
  3. Paramonova, M. P.; Khandazhinskaya, A. L.; Seley-Radtke, K. L.; Novikov, M. S. “Synthesis of novel 2-[3-[5-(4-bromophenoxy)pentyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]-N-arylacetamides as potential antivirals” Mendeleev Communications 2017, 27, 85-87.
  4. Geisman, A. N.; Valuev-Elliston, V. T.; Ozerov, A. A.; Khandazhinskaya, A. L.; Chizhov, A. O.; Kochetkov, S. N.; Pannecouque, C.; Naesens, L.; *Seley-Radtke, K. L.; Novikov, M. S. “1,6-Bis[(benzyloxy)methyl]uracil derivatives – novel antivirals with activity against HIV-1 and influenza H1N1” Bioorg Med Chem, 2016, 24, 2476-2485.
  5. Peters, H. L.; Ku, T. C.; Seley-Radtke, K. L. “Flexibility as a Strategy in Nucleoside Antiviral Drug Design”  Curr Med Chem. 2015, 22, 3910-3921.
  6. Matugina, E. S.; Novikov, M. S.; Babkov, D. A.; Ozerov, A. A.; Chernousova, L. N.; Andreevskaya, S.; Smirnova, T. G.; Karpenko, I.; Chizhov, A. O.; Muthu, P.; Lutz, S.; Kochetkov, N. S.; *Seley-Radtke, K. L.; Khandazhinskaya, A. L.; “5-Arylaminouracil derivatives: new inhibitors of M. tuberculosis” Chemical Biology & Drug Design 2015, 86, 1387-1396. *corresponding author
  7. Chen, Z.; Ku, T. C.; Seley-Radtke, K. L. “Thiophene-expanded guanosine analogues of Gemcitabine” Bioorg Med Chem Lett. 2015, 25, 4274-4276.
  8. Babkov, D. A.; Khandazhinskaya, A.; Chizhov, A. O.; Andrei, G.; Snoeck, R.; Seley-Radtke, K. L.*, Novikov, M. S. “Toward the Discovery of Dual HCMV-VZV Inhibitors: Synthesis, Structure-Activity Relationship Analysis, and Cytotoxicity Studies of Long Chained 2-Uracil-3-yl-N-(4-phenoxyphenyl)acetamides”. Bioorg Chem Med Chem 2015, 23, 7035-7044. *corresponding author.
  9. Fateev, I. V.; Kharitonova, M. I.; Esipov, R. S.; Antonov, K. V.; Konstantinova, I. D.; Stepanenko, V. N.; Seela, F.; Temburnikar, K. W.; Seley-Radtke, K. L.; Stepchenko, V. A.; Sokolov, Y. A.; Miroshnikov, A. I.; Mikhailopulo, I. A.; “Recognition of the Challenging Heterocyclic Bases by E. coli Purine Nucleoside Phosphorylase versus its Ser90Ala Mutant” Eur. J. 2015, 21, 13146-13156.
  10. Chen, Z.; Jochmans, D.; Ku, T.; Paeshuys, J.; Neyts, J.; Seley-Radtke, K. L. “Bicyclic and tricyclic nucleobase analogues of Sofosbuvir – new scaffolds for Hepatitis C therapies”, ACS Infect. Dis., 2015, 1, 357–366.
  11. Temburnikar, K.; Ross, C.; Wilson, G.; Balzarini, J.; Cawrse, B.; Seley-Radtke, K. L. ” Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines” Bioorg Med Chem 2015, 23, 4354-4363.
  12. Peters, H. L.; Jochman, D.; Posthuma, C. C.; de Wilde, A.; Snijder, E.; Neyts, J.; Seley-Radtke, K. L.; “Design, Synthesis and Anti-coronavirus Activity of a Series of Acyclic Fleximer Analogues” Bioorg Med Chem Lett 2015, 25, 2923-2926.
  13. Babkov, D. A,; Chizhov, A. O,; Khandazhinskaya, A. L.; Corona, A.; Esposito, F.; Tramontano, E.; *Seley-Radtke, K. L.; Novikov, M. S. “An efficient route to novel uracil based drug-like heterocyclesSynthesis 2015, 47,1413-1422. *corresponding author.
  14. Ross, C. R.; Temburnikar, K. W.; Wilson, G. M.; Seley-Radtke; K. L.; “Mitotic Arrest of Breast Cancer MDA-MB-231 Cells by Halogenated Thieno[3,2-d]pyrimidines” Bioorganic Med Chem Lett. 2015, 25, 1715-1717.
  15. Babkov, D. A.; Valuev-Elliston, V. T.; Paramonova, M. P.; Ozerov, A. A.; Ivanov, A. V.; Chizhov, A. O.; Khandazhinskaya, A. L.; Kochetkov, S. N.; Balzarini, J.; Dalemans, D.; Pannecouque, C.; *Seley-Radtke, K. L.; Novikov, M. S. “Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs” Bioorg Med Chem 2015, 23, 1069-1081. *corresponding author
  16. Zimmermann, S. C.; O’Neill, E.; Ebiloma, G. U.; Wallace, L. J. M.; De Koning, H. P.; Seley-Radtke, K. L. “Design and synthesis of a series of truncated neplanocin fleximers” Molecules 2014, 19, 21200-21214.
  17. Temburnikar, K.; Zimmermann, S. C.; Kim. N.; Ross, C.; Gelbmann, C.; Salomon, C.; Wilson, G.; Balzarini, J.; Seley-Radtke, K. L. “Antiproliferative activity of halogenated thieno[3,2-d]pyrimidines”, Bioorg Med Chem 2014, 22, 2113-2122.
  18. Matyugina, E. S.; Valuev-Elliston, V. T.; Gaisman, A.; Novikov, M. S.; Chizhov, A. O.; Kochetkov, S. N.; Seley-Radtke, K. L.; Khandazinskaya, A. L. “Structure-Activity Evaluation of New Uracil-Containing Non-Nucleoside Inhibitors of HIV Reverse Transcriptase” MedChemComm, 2013, 4, 1443-1451.
  19. Temburnikar, K.; Brace, K.; Seley-Radtke, K. L.”Synthesis of 2′-deoxy-9-deaza-C-nucleosides using Heck methodology”, J Org Chem, 2013, 78, 7305-7311.
  20. Novikov, M. S.; Babkov, D. A.; Paramonova, M. P.; Ozerov, A. A.; Khandazhinskaya, A. L.; Andrei, G.; Snoeck, R.; Balzarini, J.; Seley-Radtke, K. L. “Synthesis and anti-HCMV activity of 1-[w-(phenoxy)pentyl]uracil derivatives and analogues thereof” Bioorg Med Chem 2013, 21, 4151-4157.
  21. Matyugina, E. S.; Valuev-Elliston, V.; Babkov, D.; Novikov, M.; Ivanov, A.; Kutchetkov, S.; Balzarini, J.; Seley-Radtke, K. L.; Khandazhinskaya, A. L. “5′-nor carbocyclic nucleosides: surprising nonnucleoside inhibitors of HIV-1 reverse transcriptase”, MedChemComm, 2013, 4, 741-748.
  22. Zimmermann, S. C.; Sadler, J. M.; O’ Daniel, P. I.; Kim, N.T.; Seley-Radtke, K. L. ” “Reverse” Carbocyclic Fleximers. Synthesis of a New Class of Adenosine Deaminase Inhibitors” Nucleosides, Nucleotides & Nucleic Acids, 2013, 32, 137-154.
  23. Novikov, M. S., Paramonova; M. P., Babkov, D. A., Valuev-Elliston, V. T., Gavryushov, S. A. Ivanov, A. V., Kochetkov, S. N., Pannecouque, C., Andrei, G., Snoeck, R., Balzarini, J., Seley-Radtke, K. L. “N1, N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase”, Bioorg Med Chem, 2013, 21, 1150-1158.
  24. Novikov, M. S.; Babkova, D. A.; Paramonova, M. P.; Chizov, A. O., Seley-Radtke, K. L. “A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides”, Tetrahedron Letters, 2013, 54, 576-578.
  25. Wauchope, O. R.; Velasquez, M.; Seley-Radtke, K. L. “Synthetic routes to a series of proximal and distal 2′-deoxy nucleoside analogues.” Synthesis, 2012, 3496-3504.
  26. Wauchope, O. R.; Johnson, C.; Krishnamurthy, P.; Andrei, G.; Snoeck, R.; Balzarini, J.; Seley-Radtke, K. L. “Synthesis and biological evaluation of a series of thiophene-expanded purine 2′-deoxy nucleoside analogues.” Bioorg Med Chem, 2012 20, 3009-3015.
  27. Temburnikar, K.; Zhang, Z.; Seley-Radtke, K. L.: “Modified Synthesis of 3′-OTBDPS-Protected Furanoid Glycal”, Nucleosides, Nucleotides and Nucleic Acids, 2012 31, 319-327.
  28. Manvilla, B. A.; Wauchope, O.; Seley-Radtke, K. L., Drohat, A. C.; “NMR Studies Reveal an Unexpected Binding Site for a Redox Inhibitor of AP Endonuclease 1”, Biochemistry 2011 50,10540-9.
  29. Novikov, M.S.; Ivanova, O. N.; Ivanov, A.V.; Ozerov, A.A.; Valuev-Elliston, V. T.; Temburnikar, K.; Gurskaya, G. V.; Kochetkov, S. N.; Pannecouque, C.; Balzarini, J.; Seley-Radtke, K.L.; “1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents” Bioorg Med Chem 2011, 19, 5794-5802.
  30. Zimmermann, S. C.; Sadler, J. M.; Andrei, G.; Snoeck, R.; Balzarini, J.; Seley-Radtke, K. L. “Carbocyclic 5′-Nor “Reverse” Fleximers. Design, Synthesis and Preliminary Biological Activity”, MedChemComm 2011, 2, 650 – 654.
  31. Novikov, M.S.; Buckheit, R.; Temburnikar, K.; Khandazhinskaya, A. L.; Ivanov, A.V; Seley-Radtke, K.L.; “1-Benzyl derivatives of 5-(arylamino)uracils as potential anti-HIV-1 and EBV agents” Bioorg Med Chem 2010, 18, 8310-14.
  32. Wauchope, O. R.; Tomney, M. J.; Pepper, J. L.; Korba, B. E.; Seley-Radtke, K. L. 2′-C-Modified tricyclic nucleosides as potential anti-HCV therapeutics, Org Lett 2010, 12, 4466-4469.
  33. Matyugina, E. S.; Seley-Radtke, K. L.; Andronova, V. L.; Galegov, G. A.; Khandazhinskaya, A. L. Synthesis and antiviral evaluation against vaccinia virus of new N1-oxide analogues of 5’-noraristeromycin, Russian J Bioorg Chem 2010, 36, 730-733; Original Russian Text: Bioorganicheskaya Khimiya, 2010, 797–801.
  34. Tomney, M.; Korba, B.; Zimmermann, S.; Seley-Radtke, K. L. “Synthesis of a Series of 2’-Modified Tricyclic Nucleosides as Potential Anti-HCV Agents” Antiviral Res. 2010, 86, A68.
  35. Sadler, J. M.; Mosley, S. L.; Dorgan, K. M.; Zhou, Z. S.; Seley-Radtke, K. L. “Synthetic Strategies Toward Carbocyclic Purine-Pyrimidine Hybrid Nucleoside Inhibitors” Med. Chem., 2009, 17, 5520-5525.
  36. Ivanov, A.; Tunitskaya, V.; Smirnova, O.; Buckheit, R.; Seley-Radtke, K. L.; Ivanov, A.; Novikov, M. “Synthesis and Antiviral Activity of Substituted Uracils” Antiviral Res. 2009, 82, A58.
  37. Seley-Radtke, K. L.; Sunkara, N. K. “Carbocyclic Thymidine Analogues as Potential Antiviral Agents” Nucleosides, Nucleotides, Nucleic Acids 2009, 28, 633-641.
  38. O’Daniel, P. I.; Jefferson, M.; Wiest, O.; Seley-Radtke, K. L. “Computational Studies of Expanded Heterocyclic Nucleosides in DNA” J Biomol Struct Dyn, 2008, 3, 283-292. (Cover)
  39. Zhang, Z.; Wauchope, O. R.; Seley-Radtke, K. L. “Design, Synthesis and Mechanistic Studies of a Series of Expanded Xanthosine Nucleosides” Tetrahedron 2008, 64, 10791-10797.
  40. Sadler, J. M.; Ojewoye, O.; Seley-Radtke, K. L. “”Reverse Fleximers.” Introduction of a series of 5-substituted carbocyclic uridine analogues” Nucleic Acids Symp Ser. 2008, 52, 571-572.
  41. Seley-Radtke, K. L.; Zhang, Z.; Wauchope, O. R.; Zimmermann, S. C.; Ivanov, A.; Korba, B. “Hetero-expanded Purine Nucleosides. Design, Synthesis and Preliminary Biological Activity” Nucleic Acids Symp Ser. 2008, 52, 635-636.
  42. Mosley, S. L.; Bakke, B. A.; Sadler, J. M.; Dorgan, K.; Zhou, Z. S.; Seley-Radtke, K. L. “Carbocyclic Pyrimidine Nucleosides as Inhibitors of S-Adenosylhomocysteine Hydrolase”, Bioorganic Med. Chem. 2006 14, 7967-7971.
  43. Sunkara, N. K.; Mosley, S. L.; Seley-Radtke, K. L. “A Carbocyclic 7-Deaza Purine-Pyrimidine Hybrid Nucleoside” Czech. Chem. Commun., 2006, 71, 1161-1168.
  44. Quirk, S.; Seley-Radtke, K.L. “Purification, crystallization, & preliminary X-ray characterization of human GTP fucose pyrophosphorylase” Acta Cryst. 2006, F62, 392-394.
  45. Quirk, S.; Seley, K. L. “Identification of catalytic amino acids in the human GTP fucose pyrophosphorylase active site” 2005,44, 13172-13178.
  46. Quirk, S.; Seley, K. L. “Substrate discrimination by human GTP-fucose pyrophosphorylase” Biochem. 2005, 44, 10854-10863.
  47. Seley, K. L.; Salim, S.; Zhang, L.; O’Daniel, P. I. “Molecular Chameleons”. Design and Synthesis of A New Series of Flexible Nucleosides” Org. Chem. 2005, 70, 1612-1619.
  48. Seley, K. L.; Salim, S.; Zhang, L.;”Molecular Chameleons”. Design and Synthesis of C-4-Substituted Imidazole Fleximers Org, Lett. 2005, 7, 63-66.
  49. Schwimmer, J.; Rohatgi, P.; Azizi, B.; Seley, K. L.; Doyle, D. F. “Creation and Discovery of Ligand-Receptor Pairs for Small Molecule Control of Transcription” Proc. Nat. Acad. Sci. 2004, 101, 14707-14712.
  50. Polak, M.; Seley, K. L.; Plavec, J. “Conformational Properties of Novel Shaped Nucleosides – Fleximers” Am. Chem. Soc. 2004, 126, 8159-8166.
  51. Wallace, L. J. M.; Candlish, D.; Hagos, A.; Seley, K. L.; de Koning, H. P. “Selective Transport of a New Class of Purine Antimetabolites by the Protozoan Parasite Trypanosoma BruceiNucleosides, Nucleotides, Nucleic Acids 2004, 23, 1441-1444.
  52. Seley, K. L.; Mosley, S. L.; Xing, F. “Carbocyclic Isoadenosine Analogues of Neplanocin A” Letters, 2003, 5, 4401-4403.
  53. Seley, K. L.; O’Daniel, P. I.; Salim, S. “Design and Synthesis of a Series of Chlorinated 3-Deazaadenine Derivatives” Nucleosides, Nucleotides, Nucleic Acids, 2003, 22, 2133-2144.
  54. Seley, K. L.; Quirk, S.; Salim, S.; Zhang, L.; Hagos, A. “Unexpected Inhibition of S-Adenosyl-L-homocysteine Hydrolase by a Guanosine Nucleoside” Med. Chem. Lett. 2003, 13, 1985-1988.
  55. Seley, K. L.; Zhang, L.; Hagos, A.; Quirk, S. “”Fleximers”. Design and Synthesis of A New Class of Novel Shape-Modified Nucleosides” Org. Chem., 2002, 67, 3365-3373.
  56. Seley, K. L.; Zhang, L. Hagos, A. “”Fleximers”. Design and Synthesis of Two Novel Split Nucleosides” Letters, 2001, 3, 3209-3210.
  57. Barnard, D. L.; Stowell, V. D.; Seley, K. L.; Hegde, V. R.; Das, S. R.; Rajappan, V. P.; Schneller, S. W.; Smee, D. F.; Sidwell, R. W. “Inhibition of Measles Virus Replication by 5′-Nor Carbocyclic Adenosine Analogues” Antiviral Chem. Chemoth. 2001, 12, 241-250.
  58. Seley, K. L.; Januszczyk, P.; Hagos, A.; Zhang, L.; Dransfield, D.T. “Synthesis and Antitumor Activity of Thieno-Separated Tricyclic Purines” Med. Chem., 2000, 43, 4877-4883.
  59. Barnard, D. L.; Stowell, V. D.; Seley, K. L.; Hegde, V. R.; Das, S. R.; Rajappan, V. P.; Schneller, S. W. and Sidwell, R. W. “Inhibition of Measles Virus Replication by 5′-Nor Carbocyclic Nucleoside Analogs” Antiviral Res. 2000, 46, 102.
  60. Hegde, V. R.; Seley, K. L.; Schneller, S. W. Carbocyclic 5′-Norcytidine (5′-Norcarbodine)” Heterocycl. Chem. 2000, 37, 1361-1362.
  61. Hegde, V. R.; Seley, K. L.; Schneller, S. W. “Carbocyclic 5′-Noruridine” Nucleosides Nucleotides 2000, 19, 269-273.
  62. Hegde, V. R.; Seley, K. L.; Chen, X.; Schneller, S. W. “The Synthesis of Carbocyclic 5′-Nor Thymidine and an Isomer as Oligonucleotide Monomers” Nucleosides Nucleotides, 1999, 18, 1905-1910.
  63. Seley, K. L.; Schneller, S. W. “7-Deaza-5′-noraristeromycin Derivatives Resembling L-Toyocomycin and L-Sangivamycin” Heterocycl. Chem. 1999, 36, 287-288.
  64. Hegde, V. R.; Seley, K. L.; Schneller, S. W.; Elder, T. J. J. “5′-Amino-5′-deoxy-5′-noraristeromycin and Related Analogues” Org. Chem. 1998, 63, 7092-7094.
  65. Seley, K. L.; Schneller, S. W. Korba, B. “Does the Anti-HBV Activity of (+)-5′-Noraristeromycin Exist in its 4′-Epimer and 4′-Deoxygenated Derivatives?” Med. Chem. 1998, 41, 2168-2170.
  66. Seley, K. L.; Schneller, S. W.; Korba, B.; de Clercq, E.; Rattendi, D.; Lane, S.; Bacchi, C. J. “The Importance of the 4′-Hydroxyl Hydrogen for the Anti-trypanosomal and Antiviral Properties of (+)-5′-Noraristeromycin” Med. Chem. 1998, 6, 797-802.
  67. Wu, J.; Schneller, S. W.; Seley, K. L.; de Clercq, E. “Carbocyclic 7-Deazaguanine Oxetanocin Analogues” Heterocycles 1998, 47, 757-765.
  68. Wu, J.; Schneller, S. W.; Seley, K. L.; Snoeck, R.; Andrei, G.; Balzarini, J.; de Clercq, E. “Carbocyclic Oxetanocins Lacking the C-3′ Methylene” Med. Chem. 1997, 40, 1401-1406.
  69. Seley, K. L.; Schneller, S. W. Korba, B. “A 5′-Noraristeromycin Enantiomer with Activity Towards Hepatitis B Virus” Nucleosides Nucleotides 1997, 16, 2095-2099.
  70. Seley, K. L.; Schneller, S. W.; de Clercq, E. “A Methylated Derivative of 5′-Noraristeromycin” Org. Chem. 1997, 62, 5645-5646.
  71. Seley, K. L.; Schneller, S. W.; Rattendi, D.; Lane, S.; Bacchi, C. J. “Synthesis and Anti-Trypanosomal Activity of a Series of 7-Deaza-5′-noraristeromycin Derivatives Varied in the Cyclopentyl Ring” Agents Chemother. 1997, 41, 1658-1661.
  72. Seley, K. L.; Schneller, S. W.; Rattendi, D.; Lane, S.; Bacchi, C. J. “Synthesis and Anti-trypanosomal Activity of Various 8-Aza-7-deaza-5′-noraristeromycin Derivatives” Med. Chem. 1997, 40, 625-629.
  73. Seley, K. L.; Schneller, S. W.; Rattendi, D.; Bacchi, C. J. “(+)-7-Deaza-5′-noraristeromycin as an Anti-Trypanosomal Agent” Med. Chem. 1997, 40, 622-624.


Invited (Peer-reviewed) Book Chapters:

  1. Zimmermann, S. C.; Seley-Radtke, K. L. “Flexible nucleobase analogues. New tools for nucleic acid discoveries”, in RNA Technologies: DNA and RNA Chemical Biology in Science and Medicine, V. A. Erdmann, W. T. Markiewicz and J. Barciszewski eds. Springer, NY, NY 2014, pp 149-165.
  2. Seley, K. L.; Mosley, S. L. “Purine Analogues and Their Role in Methylation and Cancer Chemotherapy” in DNA Methylation and Cancer Therapy, Moshe Szyf, Ed. Landes Bioscience, Georgetown, TX, 2004, Chapter 13, pp 178-186.
  3. Seley, K. L. “Tricyclic Nucleosides Revisited” in Recent Advances in Nucleosides: Chemistry and Chemotherapy, pg. 299-326, C.K. Chu, Ed. Elsevier Science, 2002.
  4. Schneller, S. W.; Seley, K. L.; Hegde, V. R.; Rajappan, V. P. “5′-Norcarbanucleosides in L-Like Configurations” in Recent Advances in Nucleosides: Chemistry and Chemotherapy, pg. 291-297; C.K. Chu, Ed. Elsevier Science, 2002.




Invited Reviews:

  1. Seley-Radtke, K. L. “The Organic Chemistry of Drug Synthesis” by Daniel Lednicer, invited book review, J Am Chem Soc, 2008, 130, 3231-3232.
  2. Seley, K. L. “CoFactor” IDrugs, 2001, 4, 99-101.
  3. Seley, K. L. “Tezacitabine” Current Opin. Investigational Drugs 2000, 1, 135-140.
  4. Seley, K. L. “MDL 101,731” Investigational Drugs, Current Drugs Ltd, 1997.


Honors and Awards

2015-2016 President, International Society on Nucleosides, Nucleotides & Nucleic Acids (IS3NA)

2015         NIH/NCI ZCA1 SRB-2 Drug Development & Targeting Special Emphasis Panel

2014         Session Chair, 21st International Roundtable on Nucleosides, Nucleotides & Nucleic Acids, August 24-28, Poznan, Poland

2014-pres  Program Committee, International Society of Antiviral Research (ISAR)

2014         Broadening Experiences in Scientific Training, Advisory Board member, University of Notre Dame Ph.D. program

2014         Session Chair, National ACS Medicinal Chemistry Symposium, Charleston, SC, May 18, 2014

2014         Session Chair, 27th International Conference on Antiviral Research (ICAR), Raleigh, May 12-15

2014         NIH ZRG1 AARR-J PAR Panel: Sustained Release of Antivirals for Treatment or Prevention of HIV (Vice Chair)

2013-pres  Women in Chemistry Committee, ISAR

2013         NIH/NCI ZCA1 SRLB-2 Exploratory/Developmental Research study section

2013-2014 Vice President, IS3NA

2013-2016 Board of Directors, ISAR

2013-2014 Scientific Advisory Board, National ACS Medicinal Chemistry Symposium, Charleston, SC, May 18-21, 2014

2013-pres  Award Nomination & Selection Committee, ACS Medicinal Chemistry Division

2013         Session Chair, 26th ICAR, San Francisco, May 10-16

2012-pres  ISAR Poster Award Committee Chair

2012-pres  Editorial Board, Clinical Medicine Insights, Therapeutics

2012         Med Chem Session Chair, 244th National ACS meeting, Philadelphia, PA

2012         Session Chair, 4th European Workshop in Drug Synthesis, May 28, Siena, Italy

2012         Med Chem Session Chair, 243rd National ACS meeting, San Diego, CA

2012         NIH ZRG1 Member Conflict study section (ad hoc)

2011-2013 Editorial Board, Research and Reports in Medicinal Chemistry

2011         Med Chem Session Chair, 242nd National ACS meeting, Denver, CO.

2011         Session Chair, 8th European Workshop in Drug Design, May 22-28, Siena, Italy

2011-pres  Associate Editor, Current Protocols in Chemical Biology

2010-2014 NIH AIDS Discovery & Development of Therapeutics (ADDT) study section, member (Vice Chair – 2013-2014)

2010-2012 ACS Div. of Med. Chem. Long Range Planning Committee

2007-2012 Secretary, IS3NA

2010         Session Chair, 19th International Roundtable on Nucleosides, Nucleotides & Nucleic Acids, August 29-Sept 3, 2010, Lyon, France

2009         NSF Chemical Synthesis study section

2008-pres  NAS Jefferson Science Fellowship Selection Committee

2008-2012 Scientific Advisory Board, Deszyme Inc.

2008         Session Chair, 12th Indian Society of Chemists & Biologists Int. Conf. “The Interface of Chemistry-Biology in Biomedical Research“, Pilani, India

2007-pres  U.S. Embassy, Moscow Russia, Senior Science Advisor

2007         Women in International Security (WIIS) workshop “Science, Technology and U.S. National Security: Engaging the Next Generation”                                              invited panel member and discussion leader, Washington, DC

2006-pres  NAS Jefferson Science Fellow, U.S. Department of State

2005-2010 NIH/NIGMS Biomedical Research Training-A and-B study sections member

2005-pres  IS3NA, Membership (Chair), Publications & website committees

2005-pres  ISAR, Career Development Committee, Poster Awards Committee

2004-2008 Merck/AAAS Undergraduate Science Research Program (USRP) Selection Committee Member

2004         NIH Tropical Medicine & Parasitology Study Section member (ad hoc)

2004         Session Chair, International Roundtable on Nucleosides, Nucleotides and Nucleic Acids, Minneapolis, MN

2003         NIH Tropical Medicine & Parasitology Study Section member (ad hoc)

2003         Session Chair, Gordon Research Conference, Purines, Pyrimidines & Related Substances, Newport, RI

2002         NIH Bioorganic & Natural Products Study Section member (ad hoc)

2002         NIH BNZP Bioengineering Study Section member (ad hoc)


Awards and Distinctions:

2011         Outstanding Faculty Member of the Year, UMBC Honors College students

2008-2010 Inaugural Faculty Fellow, UMBC Honors College Program

2006        NAS Jefferson Science Fellow, U.S. Department of State

2006         Distinguished Faculty Award, The National Society of Collegiate Scholars

2003         ACS PROGRESS Lectureship in Chemical Sciences Award

2002         “Class Of 1940 W. Howard Ector Outstanding Teacher” Georgia Institute of Technology

1998         Outstanding Faculty Award, Cardinal Key Honor Society, Auburn University

1997         Sigma Xi Outstanding Dissertation, Auburn University

1997         Carolyn Taylor Carr Award, Auburn University

1992         American Association of University Women Scholarship, U. of South Florida

1992         Hugh Culverhouse Outstanding Graduate Student Award, U. of South Florida


Courses Taught

  • CHEM 299: Training in Experimental Chemistry (Cooperative Education)
  • CHEM 351: Organic Chemistry I
  • CHEM 351L: Organic Chemistry Laboratory I
  • CHEM 352: Organic Chemistry II
  • CHEM 352L: Organic Chemistry Laboratory II
  • CHEM 399: Tutorial Projects in Chemistry
  • CHEM 450: Chemistry of Heterocyclic Compounds
  • CHEM 453: Organic Chemistry of Nucleic Acids
  • CHEM 455: Introduction to Biomedicinal Chemistry
  • CHEM 490: Special Topics in Chemistry – Organic Synthetic Methology
  • CHEM 499: Undergraduate Research
  • CHEM 600: Advanced Laboratory Projects
  • CHEM 602: Introduction to Laboratory Research
  • CHEM 650: Chemistry of Heterocyclic Compounds
  • CHEM 653: Organic Chemistry of Nucleic Acids
  • CHEM 654: Organic Synthetic Methodology
  • CHEM 655: Introduction to Biomedicinal Chemistry
  • CHEM 713: Biochemistry/Chemistry Seminar
  • CHEM 715: Issues at the Chemistry/Biology Interface
  • CHEM 898: Pre-Candidacy Doctoral Research
  • CHEM 899: Doctoral Dissertation Research


Lab Group


Seley-Radtke Research Group